Thirty years after AIDS was first described, there is still no effective vaccine against the HIV virus. Worldwide, roughly 33 million people are HIV-positive. Researchers are working to find out whether a HIV vaccine developed by a Norwegian biotech company can be administered nasally.
In autumn 2011 the Norwegian biotechnology company Bionor Pharma reported promising findings from one of its studies: HIV patients who received the firm’s vaccine Vacc-4x, were twice as likely to not need any medications for at least a year.
The overall objective of the research being carried out by Bionor Pharma and Professor Kvale’s group is to develop a therapeutic vaccine that boosts the body’s immune response to the HIV virus, reducing the viral load (the amount of active HIV in an infected person’s blood).
“Only a small proportion of the world’s HIV-positive people have access to treatment,” points out Birger SÃ¸rensen, Bionor Pharma’s head of vaccine development. “Our hope is that a therapeutic vaccine will be an effective treatment for HIV patients all over the world.”
“If the coming studies are also successful,” says Mr SÃ¸rensen, “we hope the vaccine will be on the market within a few years.”
Join us at the 12th annual World Vaccine Congress Washington in April to hear from Dr Maja Sommerfelt, the Senior VP & CSo of Bionor Pharma on the Vacc-4x.
Get your questions ready. Have a look at the rest of the program here.
Book your ticket now to avoid disappointment.